Research Shows Diabetes Drug May Also Cut Cancer Risks

February 2014
Heart Advisor;Feb2014, Vol. 17 Issue 2, p3
The article reports on the findings of a study led by Cleveland Clinic Foundation on two commonly used diabetes drugs, which reveals the potential of insulin sensitizers to reduce the risk of cancer while reducing diabetes symptoms. According to the study, insulin sensitizers lower blood glucose and insulin levels through the expansion of the response of muscle, fat, and the liver to insulin. A comparison of insulin sensitizers with insulin secretagogues is given.


Related Articles

  • Troglitazone for insulin-resistant diabetes.  // American Family Physician;4/1/1997, Vol. 55 Issue 5, p1985 

    Presents information about the approval of the Food and Drug Administration on troglitazone (Rezulin) as the first anti-diabetes drug that targets the underlying cause of type II diabetes mellitus. Required dosage of troglitazone for patients receiving insulin injection; Most common adverse...

  • Improved Postprandial Glycemic Control With Insulin Aspart. Lindholm, Anders; McEwen, John; Riis, Anders P. // Diabetes Care;May99, Vol. 22 Issue 5, p801 

    Presents information on a study which compared the postprandial serum glucose control after administration of insulin aspart, a rapid-acting insulin analog, with that of unmodified human insulin in patients with type one diabetes. Research design and methods; Results; Conclusions.

  • Proceedings of the National Academy of Sciences: Licorice root found to contain anti-diabetic substance.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article focuses on a research, in which researchers have discovered an anti-diabetic substance in the amorfrutin class of natural substances from Licorice root.

  • In This Issue of Diabetes Care. Resnick, Helaine E. // Diabetes Care;Oct2014, Vol. 37 Issue 10, p2663 

    The article discusses various reports published within this issue including one on a study on the effect of albiglutide on diabetic patients, one on the importance of HbA testing to patients with diabetes and one on the effect of fetal hyperglycemia exposure on patients with gestational diabetes...

  • News and Trends.  // Bariatric Times;Feb2013, Vol. 10 Issue 2, p15 

    The article offers medical news brief as of February, 2013. Pennsylvania based the Living Heart Foundation has launched Heart, Obesity, Prevention, and Education (HOPE) Program with the help of the National Football League Players Association and Covidien. Woonsocket, Rhode Island based...

  • Evaluation of the Effects of Nateglinide on Postprandial Glycemia in Patients with Type 2 Diabetes mellitus: A Multicenter, Multinational, Non-Randomized, Non-Controlled Latin American Study. Islas-Andrade, Sergio; Revilla-Monsalve, Maria Cristina; Caminos, Quenemari R.; Chacín, Luis F.; Yupanqui, Hernán; López, Gloria; de la Torre, Walter; de Hurtado, Evelyn Martínez // Pharmacology;Jun2003, Vol. 68 Issue 2, p89 

    One hundred and sixteen Latin American type two diabetic patients previously only on a diet were enrolled in this multicenter, multinational, nonrandomized, noncontrolled study. Only 109 completed the study. After eight weeks of treatment with 120 mg of nateglinide, administered prior to each...

  • Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone. LEWIS, JAMES D.; FERRARA, ASSIAMIRA; PENG, TIFFANY; HEDDERSON, MONIQUE; BILKER, WARREN B.; QUESENBERRY JR., CHARLES P.; VAUGHN, DAVID J.; NESSEL, LISA; SELBY, JOSEPH; STROM, BRIAN L. // Diabetes Care;Apr2011, Vol. 34 Issue 4, p916 

    OBJECTIVE--Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy. This is an interim report of an ongoing cohort study examining the association between pioglitazone therapy and the risk of bladder cancer in patients...

  • Repeated Hypoglycemia Caused by the Overproduction of Anti-insulin Antibodies and Isolated ACTH Deficiency in a Type2 Diabetic Patient Receiving Insulin Therapy. YOSHIDA, MASANORI; MURAKAMI, MIHO; OGAWA, KOICHIRO; ASAI, MASATO; MIYATA, MISAKI; MAEDA, HARUMI; OISO, YUTAKA // Diabetes Care;Feb2013, Vol. 36 Issue 2, pe22 

    The article reports on a case of repeated hypoglycemia caused by overproduction of anti-insulin antibodies in a 46-year-old man with untreated type 2 diabetes. One year after his insulin therapy, the patient experienced frequent hypoglycemic attacks which persisted despite reducing his insulin...

  • The Effect of Oral Antidiabetic Agents on A1C Levels. Sherifali, Diana; Nerenberg, Kara; Pullenayegum, Eleanor; Cheng, Ji Emmy; Gerstein, Hertzel C. // Diabetes Care;Aug2010, Vol. 33 Issue 8, p1859 

    OBJECTIVE -- Previous reviews of the effect of oral antidiabetic (OAD) agents on A1C levels summarized studies with varying designs and methodological approaches. Using predetermined methodological criteria, we evaluated the effect of OAD agents on A1C levels. RESEARCH DESIGN AND METHODS- The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics